Blueprint Medicines Target Cancer with Genomics

April 19, 2011

April 20, 2011 | Blueprint Medicines, which announced $40 million in funding from Third Rock Ventures, is planning to develop drugs designed to target cancer cells with genomics. Founders include Gleevec developer and Cold Spring Harbor Laboratory Cancer Center. Technology Review